Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has scheduled its fourth quarter and fiscal year 2025 financial results announcement for August 7, 2025, after market close.
The company will host a webcast at 4:30 p.m. Eastern Time featuring senior management discussion of the results. The webcast will be accessible through Lifecore's investor relations website, with a replay available for 30 days following the live presentation.
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione di sviluppo e produzione a contratto (CDMO), ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'anno fiscale 2025 per il 7 agosto 2025, dopo la chiusura del mercato.
L'azienda terrà una webcast alle 16:30 ora orientale con la partecipazione del management senior che discuterà i risultati. La webcast sarà accessibile tramite il sito web delle relazioni con gli investitori di Lifecore, con una replica disponibile per 30 giorni dopo la presentazione in diretta.
Lifecore Biomedical (NASDAQ: LFCR), una organización de desarrollo y fabricación por contrato (CDMO), ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año fiscal 2025 para el 7 de agosto de 2025, después del cierre del mercado.
La compañía realizará una transmisión en vivo a las 4:30 p.m. hora del este, donde la alta dirección discutirá los resultados. La transmisión estará disponible en el sitio web de relaciones con inversionistas de Lifecore, con una repetición accesible durante 30 días después de la presentación en vivo.
Lifecore Biomedical (NASDAQ: LFCR)는 계약 개발 및 제조 조직(CDMO)으로, 2025 회계연도 4분기 및 연간 재무 실적 발표를 2025년 8월 7일 장 마감 후에 예정하고 있습니다.
회사는 동부 표준시 오후 4시 30분에 경영진이 실적을 논의하는 웹캐스트를 진행할 예정입니다. 웹캐스트는 Lifecore 투자자 관계 웹사이트를 통해 접속할 수 있으며, 생중계 후 30일간 다시보기 서비스가 제공됩니다.
Lifecore Biomedical (NASDAQ : LFCR), une organisation de développement et de fabrication sous contrat (CDMO), a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'exercice 2025 pour le 7 août 2025, après la clôture du marché.
La société organisera une webdiffusion à 16h30 heure de l'Est avec une présentation des résultats par la direction. La webdiffusion sera accessible via le site des relations investisseurs de Lifecore, avec un replay disponible pendant 30 jours après la diffusion en direct.
Lifecore Biomedical (NASDAQ: LFCR), ein Auftragsentwicklungs- und Fertigungsunternehmen (CDMO), hat die Bekanntgabe der Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2025 für den 7. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr Eastern Time ein Webcast veranstalten, bei dem das obere Management die Ergebnisse erläutert. Das Webcast ist über die Investor-Relations-Website von Lifecore zugänglich, und eine Aufzeichnung wird für 30 Tage nach der Live-Präsentation verfügbar sein.
- None.
- None.
Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern
CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss the results.
To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version of the webcast will be available on the company’s website for 30 days.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
When will Lifecore Biomedical (LFCR) report Q4 and FY 2025 earnings?
What time is Lifecore Biomedical's Q4 2025 earnings call?
How can I access Lifecore Biomedical's Q4 2025 earnings webcast?
How long will Lifecore Biomedical's Q4 2025 earnings webcast be available?
